Serum asymmetric dimethylarginine and nitric oxide levels in patients with diabetic neuropathy/Diyabetik noropatili hastalarda serum asimetrik dimetilarginin ve nitrik oksit duzeyleri

• Published in: Noro-Psikiyatri Arsivi Vol. 49; no. 3; p. 183
• Main Authors: Tamam, Yusuf, Uzar, Ertugrul, Evliyaoglu, Osman, Tay, Arzu, Kilinc, Faruk, Cevik, Mehmet Ugur
• Format: Journal Article
• Language: English
• Published: Ankara AVES 01.09.2012; BAYT Ltd. Co
• Subjects: Care and treatment; Diabetes; Diabetics; Enzyme-linked immunosorbent assay; Nitric oxide
• ISSN: 1300-0667; 1309-4866
• DOI: 10.4274/Npa.y6233

Objective: Asymmetric dimethylarginine (ADMA) is a novel marker of endothelial dysfunction. ADMA is an endothelial nitric oxide synthase inhibitor. Due to scarcity of studies on the role of ADMA in pathogenesis of diabetic neuropathy, it remains to be determined whether blood ADMA and nitric oxide (NO) levels are associated with diabetic neuropathy. In this case control study, we aimed to evaluate the relationship between serum NO and ADMA levels among diabetic neuropathy cases Methods: 48 patients with diabetic neuropathy and 34 healthy subjects were included in the study. All type 2 diabetic patients underwent electrophysiological and neurological examination. NO levels were determined using the Griess method. Serum ADMA levels were determined by using the ELISA method. Results: The serum ADMA levels in diabetic neuropathy patients were found to be statistically significantly lower than those of the control group (p=0.005). However, a statistically significant increase was observed in serum NO levels in patients with diabetic neuropathy compared with those in the control group (p = 0.009). A negative correlation was found between NO levels and ADMA levels (p=0.041, r=-0.23). Discussion: Changes in NO and ADMA levels in the blood of diabetic neuropathy patients may indicate oxidative stress and endothelial dysfunction in the pathogenesis of diabetic neuropathy. (Archives of Neuropsychiatry 2012; 49:183-187) Key words: Diabetic neuropathy, nitric oxide, ADMA, oxidative stress, endothelial dysfunction Amac: Asimetrik dimetil arginin (ADMA) endotel fonksiyon bozuklugunun yeni bir belirtecidir. ADMA endotelyal nitric oksit (NO) sentaz inhibitorudur. Diyabetik noropatinin patogenezinde ADMA'nin rolu ile ilgili cok az calisma vardir. Bu yuzden diabetik noropatinin serum ADMA ve NO duzeyleri arasinda iliski olup olmadigi belirlenmemistir. Bu vaka kontrol calismamuzda diyabetik noropatili hastalarda serum NO ve ADMA seviyeleri arasinda iliskiyi arastirmayi amacladik. Yontem: Diyabetik noropatili 48 hasta ve 34 saglikli kisi calismaya alindi. Tum tip 2 diyabetik hastalara elektrofizyolojik inceleme ve norolojik muayene yapildi. NO seviyesi Griess metoduyla belirlendi. Serum ADMA duzeyi ELISA metoduyla olculdu. Bulgular: Serum ADMA duzeyi diyabetik noropatili hastalarda kontrol grubuna gore istatistiksel olarak anlamli duzeyde azalmis bulundu (p=0,005). Bununla birlikte diyabetik noropatili hastalarda NO duzeyinde kontrol grubuna gore anlamli duzeyde artis saptandi (p=0,009). Bu calismada NO duzeyleri ile ADMA duzeyleri arasinda negative bir korelasyon bulundu (p=0,041, r=-0,23). Sonuc: Sonuc olarak diyabetik noropatili hastalarin kaninda NO ve ADMA duzeyinde degisiklikler olmasi diyabetik noropatinin patogenezinde oksidatif stresi ve endotel fonksiyon bozuklugunu isaret edebilir. (Noropsikiyatri Arsivi 2012; 49: 183-187) Anahtar kelimeler: Diabetik noropati, nitrik oksit, ADMA, oksidatif stres, endoteliyal disfonksiyon